Correlation Between Santen Pharmaceutical and Organon

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Santen Pharmaceutical and Organon at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Santen Pharmaceutical and Organon into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Santen Pharmaceutical Co and Organon Co, you can compare the effects of market volatilities on Santen Pharmaceutical and Organon and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Santen Pharmaceutical with a short position of Organon. Check out your portfolio center. Please also check ongoing floating volatility patterns of Santen Pharmaceutical and Organon.

Diversification Opportunities for Santen Pharmaceutical and Organon

0.21
  Correlation Coefficient

Modest diversification

The 3 months correlation between Santen and Organon is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Santen Pharmaceutical Co and Organon Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Organon and Santen Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Santen Pharmaceutical Co are associated (or correlated) with Organon. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Organon has no effect on the direction of Santen Pharmaceutical i.e., Santen Pharmaceutical and Organon go up and down completely randomly.

Pair Corralation between Santen Pharmaceutical and Organon

Assuming the 90 days horizon Santen Pharmaceutical Co is expected to under-perform the Organon. But the pink sheet apears to be less risky and, when comparing its historical volatility, Santen Pharmaceutical Co is 1.12 times less risky than Organon. The pink sheet trades about -0.31 of its potential returns per unit of risk. The Organon Co is currently generating about -0.2 of returns per unit of risk over similar time horizon. If you would invest  1,716  in Organon Co on August 27, 2024 and sell it today you would lose (188.00) from holding Organon Co or give up 10.96% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Santen Pharmaceutical Co  vs.  Organon Co

 Performance 
       Timeline  
Santen Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Santen Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's technical indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.
Organon 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Organon Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of sluggish performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Santen Pharmaceutical and Organon Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Santen Pharmaceutical and Organon

The main advantage of trading using opposite Santen Pharmaceutical and Organon positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Santen Pharmaceutical position performs unexpectedly, Organon can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organon will offset losses from the drop in Organon's long position.
The idea behind Santen Pharmaceutical Co and Organon Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format